Is Compounded Semaglutide the Same as Ozempic? What You Need to Know
A clear, evidence-based explanation of how compounded semaglutide compares to brand-name Ozempic and Wegovy, covering active ingredient, quality, legality, and what the FDA actually says in 2026.
Written by Trimi Medical Team. Medically reviewed by Dr. Sean Arora, MD. Last reviewed April 2026.
Quick links: Compounded semaglutide $99/mo, Compounded tirzepatide $125/mo, Top compounded GLP-1 providers.
More on GLP-1 Education
The Simple Answer (and Why It Needs More Context)
Compounded semaglutide is prepared by a licensed pharmacy against an individual prescription, and it is not an FDA-approved product in the way that Ozempic and Wegovy are. That distinction is where most of the confusion lives.
Understanding the distinction matters for patients deciding whether to start compounded semaglutide at $99/month versus brand-name Wegovy at $1,000+ per month. The cost difference is stark enough that patients deserve a clear-eyed explanation of what they're actually getting and what the legitimate considerations are, rather than either reflexively dismissing compounding or uncritically assuming brand-name and compounded are perfectly equivalent.
Key Facts About Compounded Semaglutide
Prescription-only
Compounded semaglutide is dispensed only against a valid prescription written for an individual patient after a clinician evaluation. No legitimate pharmacy sells it without one.
Prepared by a licensed pharmacy
A 503A sterile compounding pharmacy licensed by its state board prepares the medication under USP <797> standards, rather than a mass-manufacturing facility.
Not FDA-approved as a drug
Compounded preparations are not reviewed or approved by the FDA for safety or effectiveness, and they have not been studied in clinical trials.
Quality depends on the pharmacy
Sterility, potency, and beyond-use dating are controlled by the compounding pharmacy, which is why third-party batch testing and accreditation matter.
What's Different Between Compounded and Brand-Name Semaglutide
FDA regulatory status
Brand-name Wegovy/Ozempic went through rigorous FDA approval with large randomized controlled trials demonstrating efficacy and safety. Compounded semaglutide is not FDA-approved, it operates under compounding regulations (21 USC 503A and 503B) rather than drug approval processes. This is a meaningful regulatory distinction, not just a formality.
Delivery mechanism
Wegovy uses a proprietary auto-injector pen with pre-filled, precisely measured doses at specific strengths. Compounded semaglutide typically comes in multi-dose vials where the patient measures their dose with a syringe. This introduces a small potential for dosing error that doesn't exist with pre-filled pens.
Clinical evidence base
All the large clinical trials (STEP 1, STEP 2, STEP 5, FLOW, SELECT) were conducted with brand-name semaglutide. The efficacy data technically applies to the brand-name product, not to compounded versions. Most clinicians consider this distinction minor given identical molecular structure, but it is technically accurate.
Excipients and formulation
The inactive ingredients may differ. Some compounded formulations include B12, NAD+, or other additions that are not present in brand-name Ozempic or Wegovy.
The Regulatory Framework: Why Compounding Is Legal
Pharmaceutical compounding has a long legal history in the United States, governed by the Drug Quality and Security Act (DQSA) of 2013. Compounding pharmacies operate under two pathways:
503A, Traditional Compounding
Compounds for individual patients based on a valid prescription. Must comply with state pharmacy board regulations and USP standards. Can compound copies of commercially available drugs when a legitimate patient need exists and the drug is on the FDA shortage list.
503B, Outsourcing Facilities
Can produce larger batches under more stringent FDA oversight, including regular inspections similar to traditional drug manufacturers. Subject to Current Good Manufacturing Practice (CGMP) standards. Generally considered to operate under tighter quality controls than 503A pharmacies.
The legal basis for compounding semaglutide specifically is the FDA drug shortage determination. When semaglutide is listed on the FDA's drug shortage database, both 503A and 503B pharmacies have expanded authority to compound it. The shortage has been ongoing since 2022, and as of early 2026, compounded semaglutide remained legal.
Pharmacy Quality: The Variable That Matters Most
Pharmacy quality is the primary variable determining whether compounded semaglutide performs as expected. A properly formulated, correctly potent, sterile preparation from an accredited pharmacy should produce the same clinical outcomes as a brand-name product. A preparation with incorrect potency or sterility issues will not.
The questions to ask your provider about their pharmacy partners:
Is the pharmacy PCAB-accredited?
Is it registered with the FDA as a 503B outsourcing facility?
Does it perform third-party sterility and potency testing on each batch?
Is it in good standing with its state board of pharmacy?
Can you provide a Certificate of Analysis for my medication?
Trimi uses PCAB-accredited pharmacy partners and can provide documentation of pharmacy quality standards. This is the single most important factor distinguishing reputable compounded GLP-1 programs from lower-quality alternatives.
What Each Pathway Costs
Brand-Name Wegovy (semaglutide)
List price: ~$1,350/month
With Novo Nordisk coupon (eligible patients): ~$25/month
Without insurance or coupon: ~$1,100–$1,350/month
Annual cost (no coverage): ~$13,200–$16,200
Compounded Semaglutide (Trimi)
Prepared per individual prescription by a licensed pharmacy
Not FDA-approved as a drug
No insurance claim, no prior authorization, no coupon eligibility
Flat monthly price, the same at every dose
Verify current pricing directly with any provider or pharmacy before enrolling, since both brand and compounded pricing change over time.
For patients with insurance coverage for Wegovy at low or zero cost, brand-name is the obvious choice given its FDA-approved status. For the majority of patients paying out of pocket, compounded semaglutide from a quality-accredited pharmacy at $99/month represents an accessible, medically defensible alternative.
Red Flags in the Compounded Semaglutide Market
Semaglutide sold without a prescription or medical evaluation, this is illegal
Products sold as 'semaglutide peptide' or similar language to circumvent regulations
Pharmacies operating in foreign countries not subject to FDA oversight
Providers who cannot or will not share pharmacy accreditation details
Prices far below $60/month, below legitimate compounding cost floor
Claims of 'FDA-approved compounded semaglutide', compounded drugs are not FDA-approved
Frequently Asked Questions
How does compounded semaglutide differ from Ozempic and Wegovy?
Ozempic and Wegovy are FDA-approved finished drugs manufactured by Novo Nordisk. Compounded semaglutide is prepared by a licensed compounding pharmacy against an individual prescription and is not FDA-approved as a drug. The two also differ in formulation, excipients, and route to market.
Is compounded semaglutide FDA-approved?
No. Compounded semaglutide is not an FDA-approved product, it is a compounded preparation. Brand-name Ozempic (semaglutide for type 2 diabetes) and Wegovy (semaglutide for obesity) are FDA-approved. Compounded semaglutide is legal to dispense when semaglutide is on the FDA shortage list and when prepared by properly licensed compounding pharmacies (503A or 503B facilities). It operates under a different regulatory framework than FDA-approved medications.
If compounded semaglutide isn't FDA-approved, is it safe?
FDA approval and safety are related but not identical concepts. Compounded medications prepared by properly accredited pharmacies can be safe and effective. The risks associated with compounding are primarily pharmacy-quality risks, sterility failures, incorrect potency, contamination, rather than inherent molecular risks of the drug itself. PCAB-accredited compounding pharmacies operating under FDA 503A and 503B frameworks significantly mitigate these risks through quality standards, sterility testing, and regulatory oversight.
What goes into the price of Wegovy or Ozempic?
Brand-name Wegovy and Ozempic prices include R&D costs (billions spent on drug development and clinical trials), FDA approval costs, patent protection premiums, marketing budgets, and manufacturer margins. The compounded pathway has a different cost structure entirely: a licensed pharmacy sources the active ingredient and prepares it against an individual prescription, without the brand infrastructure and without FDA approval of the finished preparation.
How do I know if a compounding pharmacy is legitimate?
Verify: PCAB (Pharmacy Compounding Accreditation Board) accreditation, state board of pharmacy licensure in good standing, FDA registration for 503B outsourcing facilities, third-party sterility and potency testing documentation, and transparency about their quality processes. Your telehealth provider should be able to confirm their pharmacy partner's accreditation status. Providers who can't or won't share this information are a red flag.
What was the FDA's position on compounded semaglutide in 2026?
The FDA's position on compounded semaglutide is tied to its shortage determination. When semaglutide is on the FDA drug shortage list, 503A and 503B pharmacies can legally compound it for patients who have a medical need and a valid prescription. If the FDA removes semaglutide from the shortage list, the legal basis for compounding from 503B facilities changes. As of early 2026, compounded semaglutide remained available, though the regulatory landscape has been evolving, always verify current status with your provider.
Are there any differences between compounded semaglutide and Wegovy that patients should know about?
There are several practical differences: 1) Brand-name Wegovy uses an auto-injector pen with precise pre-filled doses; compounded semaglutide typically uses multi-dose vials and syringes requiring self-measurement. 2) Excipients (inactive ingredients) may differ. 3) Compounded versions may include additional ingredients like B12 or NAD+ in some formulations. 4) The clinical trial evidence base is for the brand-name formulation; compounded preparations have not been studied in trials and are not FDA-approved as drugs.
Sources & References
- FDA human drug compounding overview and regulations.
- NABP/PCAB compounding pharmacy accreditation standards.
- Wilding JPH, et al. Semaglutide once weekly for obesity. N Engl J Med. 2021.
- Wegovy (semaglutide) prescribing information. FDA. 2023.
- FDA drug shortage database.
- USP General Chapter 795: Non-sterile preparations. USP.
- USP General Chapter 797: Sterile preparations. USP.
Medical Disclaimer: This content is for informational purposes only and does not constitute medical advice. Trimi is one of the providers discussed. Regulatory status of compounded medications can change, verify current FDA shortage and compounding status with your provider. Consult a licensed healthcare provider before starting any GLP-1 medication.